ethyl 2-cyanoethyl(diethoxymethyl)phosphinate | 123912-25-4

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦酸及其衍生物
• 英文名称: ethyl 2-cyanoethyl(diethoxymethyl)phosphinate
• 英文别名: 3-[diethoxymethyl(ethoxy)phosphoryl]propanenitrile
• CAS: 123912-25-4
• 化学式: C₁₀H₂₀NO₄P
• 分子量: 249.247
• InChiKey: VIODSYAKJGLMRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  68.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-cyanoethyl(diethoxymethyl)phosphinate 在 镍 lithium hydroxide 、 氨 、 氢气 作用下， 以 乙醇 为溶剂， 70.0 ℃ 、10.0 MPa 条件下， 反应 4.0h， 生成 (3-氨丙基)(二乙氧基甲基)膦酸水合物
  参考文献：
  名称：

  Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists

  摘要：

  In 1987, 25 years after the synthesis of the potent and selective GABA(B) agonist baclofen (1), Kerr et al.(5) described the first GABA(B) antagonist phaclofen 2. However, phaclofen and structurally similar derivatives 3-5 did not cross the blood-brain barrier and hence were inactive in vivo as central nervous system agents. As a consequence, the therapeutic potential of GABA(B) antagonists remained unclear. In exploring GABA and baclofen derivatives by replacing the carboxylic acid residue with various phosphinic acid groups, we discovered more potent and water soluble GABA(B) antagonists. Electrophysiological experiments in vivo demonstrated that some of the new compounds were capable of penetrating the blood-brain barrier after oral administration. Neurotransmitter release experiments showed that they interacted with several presynaptic GABA(B) receptor subtypes, enhancing the release of GABA, glutamate, aspartate, and somatostatin. The new GABA(B) antagonists interacted also with postsynaptic GABA(B) receptors, as they blocked late inhibitory postsynaptic potentials. They facilitated the induction of long-term potentiation in vitro and in, vivo, suggesting potential cognition enhancing effects. Fifteen compounds were investigated in Various memory and learning paradigms in rodents. Although several compounds were found to be active, only 10 reversed the age-related deficits of old rats in a multiple-trial one-way active avoidance test after chronic treatment. The cognition facilitating effects of 10 were confirmed in learning experiments in Rhesus monkeys. The novel GABA(B) antagonists showed also protective effects in various animal models of absence epilepsy.

  DOI：

  10.1021/jm00017a016
• 作为产物：
  描述：

  β-氯丙腈 、 ethyl trimethylsilyl(diethoxymethyl)phosphonite 生成 ethyl 2-cyanoethyl(diethoxymethyl)phosphinate
  参考文献：
  名称：

  Substituted propane-phosphonous acid compounds

  摘要：

  公式##STR1##中的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基（可选择地被卤素取代）、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，苯基部分可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个是氢，或其盐。这些化合物具有宝贵的药用性能。

  公开号：

  US04656298A1

文献信息

• Substituted propane-phosponous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US05457095A1

  公开（公告）日：1995-10-10

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为 ##STR1## 的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢、C.sub.1-8-烷基、C.sub.3-6-环烷基、苯基，该苯基可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，或C.sub.7-10-苯基烷基，该苯基烷基可选择地被卤素、C.sub.1-4-烷基、C.sub.1-4-烷氧基和/或三氟甲基取代，另外两个为氢，或其盐。这些化合物具有有价值的药物性质。
• Substituted propane-phosphonuous acid compounds
  申请人：Ciba-Geigy Corporation

  公开号：US04772738A1

  公开（公告）日：1988-09-20

  The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof. These compounds have valuable pharmaceutical properties.

  式子为##STR1##的化合物，其中R.sup.1、R.sup.2和R.sup.3中的一个代表氢，C.sub.1-8-烷基，C.sub.3-6-环烷基，苯基，该苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，或C.sub.7-10-苯基烷基，该苯基烷基中的苯基可选用卤代基，C.sub.1-4-烷基，C.sub.1-4-烷氧基和/或三氟甲基，而另外两个是氢，或其盐。这些化合物具有有价值的药物特性。
• N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
  申请人：Doherty A. George

  公开号：US20050020837A1

  公开（公告）日：2005-01-27

  The present invention encompasses compounds of Formula (I) as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

  本发明涵盖公式（I）的化合物以及其药学上可接受的盐和水合物。该化合物可用于治疗免疫介导的疾病和病况，如骨髓、器官和组织移植排斥反应。包括药物组合物和使用方法。
• Selective S1P1/Edg1 receptor agonists
  申请人：——

  公开号：US20040058894A1

  公开（公告）日：2004-03-25

  The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P 1 /Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR 3 /Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions and methods of use are included.

  本发明涵盖了一种治疗哺乳动物患者免疫调节异常的方法，包括向所述患者施用一种化合物，该化合物是S1P1/Edg1受体的激动剂，其剂量足以治疗所述免疫调节异常，其中所述化合物对S1P1/Edg1受体具有选择性，而非S1PR3/Edg3受体，所述化合物的剂量足以治疗所述免疫调节异常。药物组合物和使用方法也包括在内。
• Selective s1p1/edg1 receptor agonists
  申请人：Doherty A. George

  公开号：US20050070506A1

  公开（公告）日：2005-03-31

  The present invention encompasses a method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said immunoregulatory abnormality, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor, said compound administered in an amount effective for treating said immunoregulatory abnormality. Pharmaceutical compositions are included. The invention also encompasses a method of identifying candidate compounds that are agonists of the S1P1/Edg1 receptor and which possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor. The invention further encompasses a method of treating a respiratory disease or condition in a mammalian patient in need of such treatment comprising administering to said patient a compound which is an agonist of the S1P1/Edg1 receptor in an amount effective for treating said respiratory disease or condition, wherein said compound possesses a selectivity for the S1P1/Edg1 receptor over the S1PR3/Edg3 receptor.

  本发明涵盖一种治疗哺乳动物患有免疫调节异常的方法，包括向该患者施用一种化合物，该化合物是S1P1/Edg1受体的激动剂，其用量有效治疗所述免疫调节异常，其中所述化合物对S1P1/Edg1受体优先于S1PR3/Edg3受体具有选择性，所述化合物用于治疗所述免疫调节异常的有效用量。该发明还包括制药组合物。本发明还涵盖一种识别候选化合物的方法，该化合物为S1P1/Edg1受体的激动剂，并具有对S1P1/Edg1受体优先于S1PR3/Edg3受体的选择性。本发明进一步涵盖一种治疗哺乳动物患有呼吸系统疾病或病况的方法，包括向该患者施用一种化合物，该化合物是S1P1/Edg1受体的激动剂，其用量有效治疗所述呼吸系统疾病或病况，其中所述化合物对S1P1/Edg1受体优先于S1PR3/Edg3受体具有选择性。